A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 23813
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : EGFR
Long Form : epidermal growth factor receptor
No. Year Title Co-occurring Abbreviation
2021 "Analysis of immunohistochemical expression of epidermal growth factor receptor in oral squamous cell carcinoma using tissue microarray technology and whole sections:" A comparative study. IHC, OSCC, TMAs
2021 "Metalloestrogenic" effects of cadmium downstream of G protein-coupled estrogen receptor and mitogen-activated protein kinase pathways in human uterine fibroid cells. Cd, FOXM1, GPER, PCNA
2021 18F-FDG PET/CT imaging features of Cardiac Arrhythmia - induced by Panitumumab. mAb
2021 20(S)-Ginsenoside Rg3 Inhibits Lung Cancer Cell Proliferation by Targeting EGFR-Mediated Ras/Raf/MEK/ERK Pathway. NSCLC, qRT-PCR, SCLC, TKIs
2021 4-Acetylantrocamol LT3 Inhibits Glioblastoma Cell Growth and Downregulates DNA Repair Enzyme O6-Methylguanine-DNA Methyltransferase. CREB, GBM, mTOR, PI3K, YAP
2021 89Zr-Labeled Domain II-Specific scFv-Fc ImmunoPET Probe for Imaging Epidermal Growth Factor Receptor In Vivo. DFO, p.i
2021 90Y-DOTA-nimotuzumab: Synthesis of a Promising β⁻ radiopharmaceutical. ---
2021 A bispecific decoy receptor VEGFR-EGFR/Fc binding EGF-like ligands and VEGF shows potent antitumor efficacy. VEGFR
2021 A bispecific nanobody targeting the dimerization interface of epidermal growth factor receptor: Evidence for tumor suppressive actions in vitro and in vivo. ADCC, HSA, NK, PBMCs
10  2021 A Case of Advanced Lung Adenocarcinoma Harboring an Epidermal Growth Factor Receptor(EGFR) Exon 20 Insertion, D770_N771insSVD. TKI
11  2021 A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma. ALK, EML4, FISH, IHC, LUAD
12  2021 A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. TB, TKI
13  2021 A case of hyperprogressive disease following atezolizumab therapy for pulmonary pleomorphic carcinoma with epidermal growth factor receptor mutation. GGO, HPD, PD-L1
14  2021 A Case of Metastatic Pancreatic Adenocarcinoma in Complete Remission Using Chemotherapy and Immunotherapy. FDG, MMR, PET-CT, SUV
15  2021 A case of synchronous multiple primary lung adenocarcinomas harboring epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement successfully treated with combination of osimertinib and alectinib. ALK, SMPLC
16  2021 A case report of right upper lung adenosquamous carcinoma resection following neoadjuvant targeted therapy. EBUS-GS-TBLB, PET-CT, PR
17  2021 A chemical genetic screen identifies Aurora kinases as a therapeutic target in EGFR T790M negative, gefitinib-resistant head and neck squamous cell carcinoma (HNSCC). AKIs, CDK, HNSCC, HNSCCs, HTS, NCI, NIH, NMRC, TKIs
18  2021 A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving TP53 and epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinomas (LUAD). AI, AUCs, CT, LUAD, TKIs
19  2021 A Genetically Encoded Fluorosulfonyloxybenzoyl-l-lysine for Expansive Covalent Bonding of Proteins via SuFEx Chemistry. FSY, SuFEx, UAAs
20  2021 A Lung Adenocarcinoma Patient With a Rare EGFR E709_T710delinsD Mutation Showed a Good Response to Afatinib Treatment: A Case Report and Literature Review. TKIs
21  2021 A molecular subtype of colorectal cancers initiates independently of epidermal growth factor receptor and has an accelerated growth rate mediated by IL10-dependent anergy. CRC, IL10RA
22  2021 A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations. ALK, ICIs, NSCLC, ROS1, TKIs
23  2021 A non-small cell lung cancer (NSCLC) patient with leptomeningeal metastasis harboring rare epidermal growth factor receptor (EGFR) mutations G719S and L861Q benefited from doubling dosage of osimertinib: a case report. CNS, CSF, LM, NSCLC, QD, SD
24  2021 A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma. bi-EGF-IT, FDA, HNSCC
25  2021 A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. ANO1, DCA, Dsg3, GIMAP1, SPINK1
26  2021 A Novel KIF5B-EGFR Fusion Variant in Non-Small-Cell Lung Cancer and Response to Afatinib: A Case Report. NGS, NSCLC, PFS, TKIs
27  2021 A novel osimertinib-resistant human lung adenocarcinoma cell line harbouring mutant EGFR and activated IGF1R. IGF1R, TKI
28  2021 A novel strategy for engineering of a smart generation of immune ribonucleases against EGFR+ cells. MDS, PCR, SDS-PAGE
29  2021 A Phase 1 and Biodistribution Study of ABT-806i, an 111In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806. ---
30  2021 A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study). DFS, ICI, NSCLC
31  2021 A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). BMRR, CNS, CSF, NSCLC, PFS
32  2021 A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). NSCLC, TKI
33  2021 A Potential Mechanism Underlying the Therapeutic Effects of Progesterone and Allopregnanolone on Ketamine-Induced Cognitive Deficits. ALLO, GLP-1R, MWM, PFC, PGRMC1, PI3K, PROG
34  2021 A prospective phase II study of multimodal prophylactic treatment for afatinib-induced adverse events in advanced non-small cell lung cancer (Niigata Lung Cancer Treatment Group 1401). NSCLC, PP
35  2021 A Radiobrominated Tyrosine Kinase Inhibitor for EGFR with L858R/T790M Mutations in Lung Carcinoma. BrCO1686, NSCLC, PET, TKIs
36  2021 A Rare Case of Small Cell Lung Cancer With an Epidermal Growth Factor Receptor Mutation and Its Response to Osimertinib. NSCLC, SCLC, TKI
37  2021 A rare presentation of panitumumab-involved interstitial lung disease: Spontaneous pneumomediastinum. ILD
38  2021 A Real-World Analysis of Patients with Untreated Metastatic Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Adenocarcinoma Receiving First-Line Erlotinib and Bevacizumab Combination Therapy. AE, OS, PFS
39  2021 A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study. ---
40  2021 A rotamer relay information system in the epidermal growth factor receptor-drug complexes reveals clues to new paradigm in protein conformational change. ---
41  2021 A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes. ---
42  2021 A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer. CC
43  2021 A Systematic Review of the Role of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in the Treatment of Solid Tumors. CAR-T, FDA, HER2
44  2021 A tailored LNA clamping design principle: Efficient, economized, specific and ultrasensitive for the detection of point mutations. ARMS, LNA
45  2021 A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. mAb, PK, PKs, TMDD
46  2021 Access to Tyrosine Kinase Inhibitors and Survival in Patients with Advanced EGFR+ and ALK+ Positive Non-small-cell Lung Cancer Treated in the Real-World. ALK, CI, HR, NSCLC, OS, TKIs
47  2021 ACK1 is dispensable for development, skin tumor formation, and breast cancer cell proliferation. ACK1, Cdc42
48  2021 Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer. ACSs, ALK, BRAF, FFPE, QC
49  2021 Activation of EGFR-Aurora A induces loss of primary cilia in oral squamous cell carcinoma. OLK, OSCC
50  2021 Activation of EphA2-EGFR signaling in oral epithelial cells by Candida albicans virulence factors. EphA2, OPC
51  2021 Activation of PTP1B/EGFR signaling and cytotoxicity during combined exposure to ambient electrophiles in A431 cells. BQ, ERK, HPTP1B, NQ, PTP
52  2021 Activation of the spinal EGFR signaling pathway in a rat model of cancer-induced bone pain with morphine tolerance. CIBP, MT
53  2021 Activation of the δ opioid receptor relieves cerebral ischemic injury in rats via EGFR transactivation. delta-OR, ELISA, MCAO, RTKs
54  2021 Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. EGFRex20ins, TRAE
55  2021 Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance. NSCLCs, TKIs
56  2021 ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor. ADCC, IL-2, mAbs, MICA/B, MP2, NK, OCs, OSCCs, OSCSCs, PDL1
57  2021 Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy. ALK, CNB, EBUS-TBNA, FNA, NSCLC, PD-L1, RET
58  2021 Advanced non-small cell lung cancer: Rapid evaluation of EGFR status on fine-needle cytology samples using Idylla. CT, FNAC, NSCLC, ROSE, US
59  2021 Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis. ALK, LM, NSCLC, OS, TKI
60  2021 Adverse event profiles of epidermal growth factor receptor-tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. AEs, EGFR-TKIs, RCTs, RR
61  2021 Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice. NSCLC, ORR, OS, PFS, TKIs
62  2021 Airway Epithelial Cells Drive Airway Smooth Muscle Cell Phenotype Switching to the Proliferative and Pro-inflammatory Phenotype. ASM, ASMC, HB-EGF, Mnt
63  2021 Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. LANCL2, LUAD
64  2021 Alisertib inhibits migration and invasion of EGFR-TKI resistant cells by partially reversing the epithelial-mesenchymal transition. AURKA, EMT, NSCLC, TKIs
65  2021 Alkaloid and acetogenin-rich fraction from Annona crassiflora fruit peel inhibits proliferation and migration of human liver cancer HepG2 cells. AF-Ac, PCNA
66  2021 Allosteric Inhibition of the Epidermal Growth Factor Receptor. JM
67  2021 Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling. ALOC-EO, HB-EGF
68  2021 Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma. RTKs, TGF-alpha
69  2021 Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. Exon20ins, NSCLC
70  2021 Amivantamab: First Approval. MET, NSCLC
71  2021 Amphiregulin increases migration and proliferation of epithelial ovarian cancer cells by inducing its own expression via PI3-kinase signaling. AREG, EOC, MAPK, PI3K
72  2021 Amphiregulin Regulates Melanocytic Senescence. AREG, OIS
73  2021 Amphiregulin stimulates human chorionic gonadotropin expression by inducing ERK1/2-mediated ID3 expression in trophoblast cells. AREG, hCG, ID3
74  2021 An effective polymeric nanocarrier that allows for active targeting and selective drug delivery in cell coculture systems. CD147
75  2021 An evidence update on the protective mechanism of tangeretin against neuroinflammation based on network pharmacology prediction and transcriptomic analysis. INSR, MAPK, mTOR, PI3K, VEGFA
76  2021 An in vitro model of tumor heterogeneity resolves genetic, epigenetic, and stochastic sources of cell state variability. GO, NSCLC
77  2021 An integrated computational pipeline for designing high-affinity nanobodies with expanded genetic codes. nnAAs, SPR
78  2021 An overview of osimertinib as a treatment of non-small cell lung cancer (NSCLC): an update. NSCLC, TKI
79  2021 Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study. BM, CI, CNS, cORR, cPFS, LM, NSCLC
80  2021 Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor-positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. CI, ctDNA, dPCR, HR, MAF, NSCLC, OS, TKIs
81  2021 Analysis of EGFR Mutation Status in Algerian Patients with Non-Small Cell Lung Cancer. NSCLC
82  2021 Analysis of Increased EGFR and IGF-1R Signaling and Its Correlation with Socio-Epidemiological Features and Biological Profile in Breast Cancer Patients: A Study in Northern Brazil. AUC, BC, IGF-1R
83  2021 Analysis of Intestinal Flora and Levels of Epidermal Growth Factor Receptor, Interleukin-32, and Gastrin 17 in Patients with Gastric Cancer via Carbon Nanoparticle Laparoscopy. IL-32
84  2021 Analysis of metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. NSCLC
85  2021 Analysis of risk factors for skin disorders caused by anti-epidermal growth factor receptor antibody drugs and examination of methods for their avoidance. ---
86  2021 Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma. CGGA, GBM, LGG, MSKCC, SPATS2L
87  2021 Angiogenic activities are increased via upregulation of HIF-1α expression in gefitinib-resistant non-small cell lung carcinoma cells. HIF-1, NSCLC
88  2021 Angiotensin II-induced overexpression of sirtuin 1 contributes to enhanced expression of Giα proteins and hyperproliferation of vascular smooth muscle cells. Ang II, IGFR, MAP, PDGFR, SIRT1, VSMCs
89  2021 Angiotensin II-Induced Vasoconstriction via Rho Kinase Activation in Pressure-Overloaded Rat Thoracic Aortas. Ang II, JAK2, MLC, MYPT1
90  2021 Anti-Cancer Effects of Zotarolimus Combined with 5-Fluorouracil Treatment in HCT-116 Colorectal Cancer-Bearing BALB/c Nude Mice. COX-2, ERK, mTOR, TGF-beta, VEGF
91  2021 Anti-EGFR antibody 528 binds to domain III of EGFR at a site shifted from the cetuximab epitope. ---
92  2021 Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy. ADC, TNBCs
93  2021 Anti-tumor effect of trametinib in bladder cancer organoid and the underlying mechanism. BC
94  2021 Anti-tumoral activity of the Pan-HER (Sym013) antibody mixture in gemcitabine-resistant pancreatic cancer models. ---
95  2021 Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. CRC, mCRC, TKIs, VEGF
96  2021 Anticancer Activity and Mechanisms of Action of New Chimeric EGFR/HDAC-Inhibitors. HDACs
97  2021 Anticancer potential of some imidazole and fused imidazole derivatives: exploring the mechanism via epidermal growth factor receptor (EGFR) inhibition. ---
98  2021 Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells. ARO
99  2021 Antitumor Activity of Nanoparticles Loaded with PHT-427, a Novel AKT/PDK1 Inhibitor, for the Treatment of Head and Neck Squamous Cell Carcinoma. alpha-TOS, HNSCC, NPs, PI3K, ROS
100  2021 Antitumor Effects of Ursolic Acid through Mediating the Inhibition of STAT3/PD-L1 Signaling in Non-Small Cell Lung Cancer Cells. PD-L1, UA, VEGF